{ "format" : "linked-data-api", "version" : "0.2", "result" : {"_about" : "http://eldaddp.azurewebsites.net/answeredquestions.text?date=2015-07-01&answeringDeptId=17", "definition" : "http://eldaddp.azurewebsites.net/meta/answeredquestions.text?date=2015-07-01&answeringDeptId=17", "extendedMetadataVersion" : "http://eldaddp.azurewebsites.net/answeredquestions.text?date=2015-07-01&answeringDeptId=17&_metadata=all", "first" : "http://eldaddp.azurewebsites.net/answeredquestions.text?date=2015-07-01&_page=0&answeringDeptId=17", "hasPart" : "http://eldaddp.azurewebsites.net/answeredquestions.text?date=2015-07-01&answeringDeptId=17", "isPartOf" : "http://eldaddp.azurewebsites.net/answeredquestions.text?date=2015-07-01&answeringDeptId=17", "items" : [{"_about" : "http://data.parliament.uk/resources/386884", "AnsweringBody" : [{"_value" : "Department of Health"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/386884/answer", "answerText" : {"_value" : "

This is a single centre study at University College London Hospital. It has now been set up and one patient has been recruited and scanned. The current planned date for end of recruitment is 1 October 2016. It is anticipated that the data will be analysed and submitted for publication in a peer reviewed journal within a year of the end of recruitment.<\/p>

<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/127", "label" : {"_value" : "Biography information for Lord Prior of Brampton"} } , "answeringMemberPrinted" : {"_value" : "Lord Prior of Brampton"} , "dateOfAnswer" : {"_value" : "2015-07-14", "_datatype" : "dateTime"} , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2015-07-14T15:36:20.96Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "17"} , "answeringDeptShortName" : {"_value" : "Health"} , "answeringDeptSortName" : {"_value" : "Health"} , "date" : {"_value" : "2015-07-01", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Amyloidosis"} , "houseId" : {"_value" : "2"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25277", "prefLabel" : {"_value" : "House of Lords"} } ], "questionText" : "To ask Her Majesty\u2019s Government what progress has been made on setting up a study to image amyloid deposition in systemic amyloidosis using hybrid positron emission tomography-magnetic resonance imaging; where the study is located; how many patients have been recruited; when the study is expected to complete its initial work; and where the results will be published.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4151", "label" : {"_value" : "Biography information for Lord Willis of Knaresborough"} } , "tablingMemberPrinted" : [{"_value" : "Lord Willis of Knaresborough"} ], "uin" : "HL993"} , {"_about" : "http://data.parliament.uk/resources/386885", "AnsweringBody" : [{"_value" : "Department of Health"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/386885/answer", "answerText" : {"_value" : "

This trial is led by the University of Birmingham. The project is recruiting ahead of schedule and expects to reach its target of 800 in the near future. The target was to do so by the end of November 2015. Publication of initial findings is expected in 2017.<\/p>

<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/127", "label" : {"_value" : "Biography information for Lord Prior of Brampton"} } , "answeringMemberPrinted" : {"_value" : "Lord Prior of Brampton"} , "dateOfAnswer" : {"_value" : "2015-07-09", "_datatype" : "dateTime"} , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2015-07-09T13:00:57.7Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "17"} , "answeringDeptShortName" : {"_value" : "Health"} , "answeringDeptSortName" : {"_value" : "Health"} , "date" : {"_value" : "2015-07-01", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Multiple Myeloma"} , "houseId" : {"_value" : "2"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25277", "prefLabel" : {"_value" : "House of Lords"} } ], "questionText" : "To ask Her Majesty\u2019s Government when they expect the National Institute of Health Research Technology Assessment programme to publish initial findings from its assessment of the benefits of antibiotic prophylaxis and its effect on healthcare associated infections in myeloma patients.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4151", "label" : {"_value" : "Biography information for Lord Willis of Knaresborough"} } , "tablingMemberPrinted" : [{"_value" : "Lord Willis of Knaresborough"} ], "uin" : "HL994"} , {"_about" : "http://data.parliament.uk/resources/386886", "AnsweringBody" : [{"_value" : "Department of Health"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/386886/answer", "answerText" : {"_value" : "

There are four trials for systemic amyloidosis that are designated as \u2018ongoing\u2019 in the United Kingdom. These are being conducted by two commercial sponsors, Millennium Pharmaceuticals Inc and A.T. Development Switzerland Sarl (two studies), and one non-commercial sponsor, European Myeloma Network.<\/p>

<\/p>

<\/p>

<\/p>

Clinical trial sponsors are required to publish a summary of their trial results to the EU Clinical Trials Register within one year of their trial completing. At that point, these results will become publically available on the EU Clinical Trials Register<\/p>

<\/p>

<\/p>

<\/p>

The Department of Health, which funds the National Institute for Health Research (NIHR), is a member of the National Cancer Research Institute (NCRI). NCRI Clinical Studies Groups (CSGs) bring together clinicians, scientists, statisticians and lay representatives to coordinate development of a strategic portfolio of trials within their field. All CSGs interact with clinical research networks, funders (including NIHR) and researchers to develop studies aimed at improving outcomes for patients. The Haematological Oncology CSG has a Myeloma Subgroup and its 2013-14 annual report that includes an assessment of progress in these areas is attached and available on the NCRI website at:<\/p>

<\/p>

http://csg.ncri.org.uk/wp-content/uploads/2014/11/NCRI-Haem-Onc-CSG-Annual-Report-2013-14.pdf<\/a>.<\/p>

<\/p>

<\/p>

<\/p>

We cannot comment on commercial considerations. When the results are known, the commercial potential of these trial\u2019s products will be a matter for the respective trial sponsors.<\/p>

<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/127", "label" : {"_value" : "Biography information for Lord Prior of Brampton"} } , "answeringMemberPrinted" : {"_value" : "Lord Prior of Brampton"} , "attachment" : {"_about" : "http://data.parliament.uk/resources/386886/answer/attachment/1", "fileName" : {"_value" : "NCRI-Haem-Onc-CSG-Annual-Report-2013-14.pdf"} , "title" : "2013-14 Annual Report"} , "dateOfAnswer" : {"_value" : "2015-07-14", "_datatype" : "dateTime"} , "groupedQuestionUIN" : [{"_value" : "HL996"} , {"_value" : "HL997"} ], "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2015-07-14T15:34:29.197Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "17"} , "answeringDeptShortName" : {"_value" : "Health"} , "answeringDeptSortName" : {"_value" : "Health"} , "date" : {"_value" : "2015-07-01", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Amyloidosis and Multiple Myeloma"} , "houseId" : {"_value" : "2"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25277", "prefLabel" : {"_value" : "House of Lords"} } ], "questionText" : "To ask Her Majesty\u2019s Government whether they will place in the Library of the House any publications resulting from the phase 3 clinical trials approved for the potential treatment of systemic amyloidosis or multiple myeloma; and what is the National Institute of Health Research\u2019s assessment of progress in these areas.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4151", "label" : {"_value" : "Biography information for Lord Willis of Knaresborough"} } , "tablingMemberPrinted" : [{"_value" : "Lord Willis of Knaresborough"} ], "uin" : "HL995"} , {"_about" : "http://data.parliament.uk/resources/386887", "AnsweringBody" : [{"_value" : "Department of Health"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/386887/answer", "answerText" : {"_value" : "

There are four trials for systemic amyloidosis that are designated as \u2018ongoing\u2019 in the United Kingdom. These are being conducted by two commercial sponsors, Millennium Pharmaceuticals Inc and A.T. Development Switzerland Sarl (two studies), and one non-commercial sponsor, European Myeloma Network.<\/p>

<\/p>

<\/p>

<\/p>

Clinical trial sponsors are required to publish a summary of their trial results to the EU Clinical Trials Register within one year of their trial completing. At that point, these results will become publically available on the EU Clinical Trials Register<\/p>

<\/p>

<\/p>

<\/p>

The Department of Health, which funds the National Institute for Health Research (NIHR), is a member of the National Cancer Research Institute (NCRI). NCRI Clinical Studies Groups (CSGs) bring together clinicians, scientists, statisticians and lay representatives to coordinate development of a strategic portfolio of trials within their field. All CSGs interact with clinical research networks, funders (including NIHR) and researchers to develop studies aimed at improving outcomes for patients. The Haematological Oncology CSG has a Myeloma Subgroup and its 2013-14 annual report that includes an assessment of progress in these areas is attached and available on the NCRI website at:<\/p>

<\/p>

http://csg.ncri.org.uk/wp-content/uploads/2014/11/NCRI-Haem-Onc-CSG-Annual-Report-2013-14.pdf<\/a>.<\/p>

<\/p>

<\/p>

<\/p>

We cannot comment on commercial considerations. When the results are known, the commercial potential of these trial\u2019s products will be a matter for the respective trial sponsors.<\/p>

<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/127", "label" : {"_value" : "Biography information for Lord Prior of Brampton"} } , "answeringMemberPrinted" : {"_value" : "Lord Prior of Brampton"} , "attachment" : {"_about" : "http://data.parliament.uk/resources/386887/answer/attachment/1", "fileName" : {"_value" : "NCRI-Haem-Onc-CSG-Annual-Report-2013-14.pdf"} , "title" : "2013-14 Annual Report"} , "dateOfAnswer" : {"_value" : "2015-07-14", "_datatype" : "dateTime"} , "groupedQuestionUIN" : [{"_value" : "HL995"} , {"_value" : "HL997"} ], "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2015-07-14T15:34:29.297Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "17"} , "answeringDeptShortName" : {"_value" : "Health"} , "answeringDeptSortName" : {"_value" : "Health"} , "date" : {"_value" : "2015-07-01", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Amyloidosis"} , "houseId" : {"_value" : "2"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25277", "prefLabel" : {"_value" : "House of Lords"} } ], "questionText" : "To ask Her Majesty\u2019s Government whether there are currently any trials for systemic amyloidosis in humans being conducted by the National Institute of Health Research charities or the commercial sector.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4151", "label" : {"_value" : "Biography information for Lord Willis of Knaresborough"} } , "tablingMemberPrinted" : [{"_value" : "Lord Willis of Knaresborough"} ], "uin" : "HL996"} , {"_about" : "http://data.parliament.uk/resources/386888", "AnsweringBody" : [{"_value" : "Department of Health"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/386888/answer", "answerText" : {"_value" : "

There are four trials for systemic amyloidosis that are designated as \u2018ongoing\u2019 in the United Kingdom. These are being conducted by two commercial sponsors, Millennium Pharmaceuticals Inc and A.T. Development Switzerland Sarl (two studies), and one non-commercial sponsor, European Myeloma Network.<\/p>

<\/p>

<\/p>

<\/p>

Clinical trial sponsors are required to publish a summary of their trial results to the EU Clinical Trials Register within one year of their trial completing. At that point, these results will become publically available on the EU Clinical Trials Register<\/p>

<\/p>

<\/p>

<\/p>

The Department of Health, which funds the National Institute for Health Research (NIHR), is a member of the National Cancer Research Institute (NCRI). NCRI Clinical Studies Groups (CSGs) bring together clinicians, scientists, statisticians and lay representatives to coordinate development of a strategic portfolio of trials within their field. All CSGs interact with clinical research networks, funders (including NIHR) and researchers to develop studies aimed at improving outcomes for patients. The Haematological Oncology CSG has a Myeloma Subgroup and its 2013-14 annual report that includes an assessment of progress in these areas is attached and available on the NCRI website at:<\/p>

<\/p>

http://csg.ncri.org.uk/wp-content/uploads/2014/11/NCRI-Haem-Onc-CSG-Annual-Report-2013-14.pdf<\/a>.<\/p>

<\/p>

<\/p>

<\/p>

We cannot comment on commercial considerations. When the results are known, the commercial potential of these trial\u2019s products will be a matter for the respective trial sponsors.<\/p>

<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/127", "label" : {"_value" : "Biography information for Lord Prior of Brampton"} } , "answeringMemberPrinted" : {"_value" : "Lord Prior of Brampton"} , "attachment" : {"_about" : "http://data.parliament.uk/resources/386888/answer/attachment/1", "fileName" : {"_value" : "NCRI-Haem-Onc-CSG-Annual-Report-2013-14.pdf"} , "title" : "2013-14 Annual Report"} , "dateOfAnswer" : {"_value" : "2015-07-14", "_datatype" : "dateTime"} , "groupedQuestionUIN" : [{"_value" : "HL995"} , {"_value" : "HL996"} ], "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2015-07-14T15:34:29.553Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "17"} , "answeringDeptShortName" : {"_value" : "Health"} , "answeringDeptSortName" : {"_value" : "Health"} , "date" : {"_value" : "2015-07-01", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Amyloidosis"} , "houseId" : {"_value" : "2"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25277", "prefLabel" : {"_value" : "House of Lords"} } ], "questionText" : "To ask Her Majesty\u2019s Government which of the four phase 2 or 3 clinical trials for systemic amyloidosis approved since 2004 are still ongoing; and whether any of the trials have produced sufficient positive outcomes to encourage commercial development.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4151", "label" : {"_value" : "Biography information for Lord Willis of Knaresborough"} } , "tablingMemberPrinted" : [{"_value" : "Lord Willis of Knaresborough"} ], "uin" : "HL997"} , {"_about" : "http://data.parliament.uk/resources/386891", "AnsweringBody" : [{"_value" : "Department of Health"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/386891/answer", "answerText" : {"_value" : "

Information on high risk groups suffering neural tube defects at birth is not collected centrally.<\/p>

<\/p>

<\/p>

<\/p>

There are no current mechanisms in place for monitoring the take-up of advice given on the NHS Choices website about preventing spina bifida.<\/p>

<\/p>

<\/p>

<\/p>

The British Isles Network of Congenital Anomaly Registers (BINOCAR) collects information about the mother and child, including postcode of residence, mother\u2019s age, pregnancy length, pregnancy outcome, when and how the anomaly was identified and the details of each anomaly.<\/p>

<\/p>

<\/p>

<\/p>

Information on congenital abnormalities including spina bifida, hydrocephalus and anencephaly is collected by the British Isles Network of Congenital Anomaly Registers. Data is currently available for 2009\u20132012.<\/p>

<\/p>

<\/p>

<\/p>

The following table shows the number of live births for years 2009-2012<\/p>

<\/p>

<\/strong><\/p>

<\/p>

Number of cases, birth prevalence (per 10,000 total births) and 95% CIs according to congenital anomaly subgroup; six BINOCAR registers (coverage: 36% of births in England and Wales): 2009-2012 \u2013 Live Births<\/p><\/td><\/tr>

<\/p><\/td>

2009<\/p><\/td>

2010<\/p><\/td>

2011<\/p><\/td>

2012<\/p><\/td><\/tr>

Congenital anomaly<\/p>

<\/p><\/td>

<\/p><\/td>

<\/p><\/td>

<\/p><\/td>

<\/p><\/td><\/tr>

Spina bifida<\/p>

<\/p><\/td>

31<\/p><\/td>

53<\/p><\/td>

34<\/p><\/td>

44<\/p><\/td><\/tr>

Hydrocephalus<\/p>

<\/p><\/td>

48<\/p><\/td>

85<\/p><\/td>

72<\/p><\/td>

84<\/p><\/td><\/tr>

Anencephalus and similar<\/p>

<\/p><\/td>

4<\/p><\/td>

4<\/p><\/td>

1<\/p><\/td>

6<\/p><\/td><\/tr><\/tbody><\/table>

<\/p>

<\/strong><\/p>

<\/p>

In line with National Institute for Health and Care Excellence guidelines, health professionals use appropriate opportunities to advise all women who may become pregnant that they can most easily reduce the risk of having a baby with a neural tube defect by taking folic acid supplements. This information is also available on the NHS Choices website.<\/p>

<\/p>

<\/strong><\/p>

<\/p>

The Scientific Advisory Committee on Nutrition (SACN) was, however, commissioned to provide advice to government on the impact of folic acid fortification to improve the folate status of women and therefore reduce the number of pregnancies affected by neural tube defects. This built on previous advice from SACN\u2019s predecessor the Committee on Medical Aspects of Food and Nutrition Policy in 2000. The Government is currently considering the recommendations that SACN made alongside other information sources, including the latest folate status data and expects to make an announcement on this in due course.<\/p>

<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/127", "label" : {"_value" : "Biography information for Lord Prior of Brampton"} } , "answeringMemberPrinted" : {"_value" : "Lord Prior of Brampton"} , "dateOfAnswer" : {"_value" : "2015-07-14", "_datatype" : "dateTime"} , "groupedQuestionUIN" : [{"_value" : "HL1001"} , {"_value" : "HL1002"} , {"_value" : "HL1003"} , {"_value" : "HL1004"} , {"_value" : "HL1005"} ], "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2015-07-14T14:37:07.203Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "17"} , "answeringDeptShortName" : {"_value" : "Health"} , "answeringDeptSortName" : {"_value" : "Health"} , "date" : {"_value" : "2015-07-01", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Neural Tube Defects"} , "houseId" : {"_value" : "2"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25277", "prefLabel" : {"_value" : "House of Lords"} } ], "questionText" : "To ask Her Majesty\u2019s Government what is the latest information they have regarding high risk groups suffering neural tube defects at birth.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/302", "label" : {"_value" : "Biography information for Lord Rooker"} } , "tablingMemberPrinted" : [{"_value" : "Lord Rooker"} ], "uin" : "HL1000"} , {"_about" : "http://data.parliament.uk/resources/386892", "AnsweringBody" : [{"_value" : "Department of Health"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/386892/answer", "answerText" : {"_value" : "

Information on high risk groups suffering neural tube defects at birth is not collected centrally.<\/p>

<\/p>

<\/p>

<\/p>

There are no current mechanisms in place for monitoring the take-up of advice given on the NHS Choices website about preventing spina bifida.<\/p>

<\/p>

<\/p>

<\/p>

The British Isles Network of Congenital Anomaly Registers (BINOCAR) collects information about the mother and child, including postcode of residence, mother\u2019s age, pregnancy length, pregnancy outcome, when and how the anomaly was identified and the details of each anomaly.<\/p>

<\/p>

<\/p>

<\/p>

Information on congenital abnormalities including spina bifida, hydrocephalus and anencephaly is collected by the British Isles Network of Congenital Anomaly Registers. Data is currently available for 2009\u20132012.<\/p>

<\/p>

<\/p>

<\/p>

The following table shows the number of live births for years 2009-2012<\/p>

<\/p>

<\/strong><\/p>

<\/p>

Number of cases, birth prevalence (per 10,000 total births) and 95% CIs according to congenital anomaly subgroup; six BINOCAR registers (coverage: 36% of births in England and Wales): 2009-2012 \u2013 Live Births<\/p><\/td><\/tr>

<\/p><\/td>

2009<\/p><\/td>

2010<\/p><\/td>

2011<\/p><\/td>

2012<\/p><\/td><\/tr>

Congenital anomaly<\/p>

<\/p><\/td>

<\/p><\/td>

<\/p><\/td>

<\/p><\/td>

<\/p><\/td><\/tr>

Spina bifida<\/p>

<\/p><\/td>

31<\/p><\/td>

53<\/p><\/td>

34<\/p><\/td>

44<\/p><\/td><\/tr>

Hydrocephalus<\/p>

<\/p><\/td>

48<\/p><\/td>

85<\/p><\/td>

72<\/p><\/td>

84<\/p><\/td><\/tr>

Anencephalus and similar<\/p>

<\/p><\/td>

4<\/p><\/td>

4<\/p><\/td>

1<\/p><\/td>

6<\/p><\/td><\/tr><\/tbody><\/table>

<\/p>

<\/strong><\/p>

<\/p>

In line with National Institute for Health and Care Excellence guidelines, health professionals use appropriate opportunities to advise all women who may become pregnant that they can most easily reduce the risk of having a baby with a neural tube defect by taking folic acid supplements. This information is also available on the NHS Choices website.<\/p>

<\/p>

<\/strong><\/p>

<\/p>

The Scientific Advisory Committee on Nutrition (SACN) was, however, commissioned to provide advice to government on the impact of folic acid fortification to improve the folate status of women and therefore reduce the number of pregnancies affected by neural tube defects. This built on previous advice from SACN\u2019s predecessor the Committee on Medical Aspects of Food and Nutrition Policy in 2000. The Government is currently considering the recommendations that SACN made alongside other information sources, including the latest folate status data and expects to make an announcement on this in due course.<\/p>

<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/127", "label" : {"_value" : "Biography information for Lord Prior of Brampton"} } , "answeringMemberPrinted" : {"_value" : "Lord Prior of Brampton"} , "dateOfAnswer" : {"_value" : "2015-07-14", "_datatype" : "dateTime"} , "groupedQuestionUIN" : [{"_value" : "HL1000"} , {"_value" : "HL1002"} , {"_value" : "HL1003"} , {"_value" : "HL1004"} , {"_value" : "HL1005"} ], "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2015-07-14T14:37:07.313Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "17"} , "answeringDeptShortName" : {"_value" : "Health"} , "answeringDeptSortName" : {"_value" : "Health"} , "date" : {"_value" : "2015-07-01", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Spina Bifida: Health Education"} , "houseId" : {"_value" : "2"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25277", "prefLabel" : {"_value" : "House of Lords"} } ], "questionText" : "To ask Her Majesty\u2019s Government how the take-up of advice given on National Health Service websites about preventing spina bifida is currently monitored.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/302", "label" : {"_value" : "Biography information for Lord Rooker"} } , "tablingMemberPrinted" : [{"_value" : "Lord Rooker"} ], "uin" : "HL1001"} , {"_about" : "http://data.parliament.uk/resources/386893", "AnsweringBody" : [{"_value" : "Department of Health"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/386893/answer", "answerText" : {"_value" : "

Information on high risk groups suffering neural tube defects at birth is not collected centrally.<\/p>

<\/p>

<\/p>

<\/p>

There are no current mechanisms in place for monitoring the take-up of advice given on the NHS Choices website about preventing spina bifida.<\/p>

<\/p>

<\/p>

<\/p>

The British Isles Network of Congenital Anomaly Registers (BINOCAR) collects information about the mother and child, including postcode of residence, mother\u2019s age, pregnancy length, pregnancy outcome, when and how the anomaly was identified and the details of each anomaly.<\/p>

<\/p>

<\/p>

<\/p>

Information on congenital abnormalities including spina bifida, hydrocephalus and anencephaly is collected by the British Isles Network of Congenital Anomaly Registers. Data is currently available for 2009\u20132012.<\/p>

<\/p>

<\/p>

<\/p>

The following table shows the number of live births for years 2009-2012<\/p>

<\/p>

<\/strong><\/p>

<\/p>

Number of cases, birth prevalence (per 10,000 total births) and 95% CIs according to congenital anomaly subgroup; six BINOCAR registers (coverage: 36% of births in England and Wales): 2009-2012 \u2013 Live Births<\/p><\/td><\/tr>

<\/p><\/td>

2009<\/p><\/td>

2010<\/p><\/td>

2011<\/p><\/td>

2012<\/p><\/td><\/tr>

Congenital anomaly<\/p>

<\/p><\/td>

<\/p><\/td>

<\/p><\/td>

<\/p><\/td>

<\/p><\/td><\/tr>

Spina bifida<\/p>

<\/p><\/td>

31<\/p><\/td>

53<\/p><\/td>

34<\/p><\/td>

44<\/p><\/td><\/tr>

Hydrocephalus<\/p>

<\/p><\/td>

48<\/p><\/td>

85<\/p><\/td>

72<\/p><\/td>

84<\/p><\/td><\/tr>

Anencephalus and similar<\/p>

<\/p><\/td>

4<\/p><\/td>

4<\/p><\/td>

1<\/p><\/td>

6<\/p><\/td><\/tr><\/tbody><\/table>

<\/p>

<\/strong><\/p>

<\/p>

In line with National Institute for Health and Care Excellence guidelines, health professionals use appropriate opportunities to advise all women who may become pregnant that they can most easily reduce the risk of having a baby with a neural tube defect by taking folic acid supplements. This information is also available on the NHS Choices website.<\/p>

<\/p>

<\/strong><\/p>

<\/p>

The Scientific Advisory Committee on Nutrition (SACN) was, however, commissioned to provide advice to government on the impact of folic acid fortification to improve the folate status of women and therefore reduce the number of pregnancies affected by neural tube defects. This built on previous advice from SACN\u2019s predecessor the Committee on Medical Aspects of Food and Nutrition Policy in 2000. The Government is currently considering the recommendations that SACN made alongside other information sources, including the latest folate status data and expects to make an announcement on this in due course.<\/p>

<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/127", "label" : {"_value" : "Biography information for Lord Prior of Brampton"} } , "answeringMemberPrinted" : {"_value" : "Lord Prior of Brampton"} , "dateOfAnswer" : {"_value" : "2015-07-14", "_datatype" : "dateTime"} , "groupedQuestionUIN" : [{"_value" : "HL1000"} , {"_value" : "HL1001"} , {"_value" : "HL1003"} , {"_value" : "HL1004"} , {"_value" : "HL1005"} ], "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2015-07-14T14:37:07.437Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "17"} , "answeringDeptShortName" : {"_value" : "Health"} , "answeringDeptSortName" : {"_value" : "Health"} , "date" : {"_value" : "2015-07-01", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Neural Tube Defects"} , "houseId" : {"_value" : "2"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25277", "prefLabel" : {"_value" : "House of Lords"} } ], "questionText" : "To ask Her Majesty\u2019s Government how many live births where the child was diagnosed with spina bifida, hydrocephalus or anencephaly there have been in each of the past five years.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/302", "label" : {"_value" : "Biography information for Lord Rooker"} } , "tablingMemberPrinted" : [{"_value" : "Lord Rooker"} ], "uin" : "HL1002"} , {"_about" : "http://data.parliament.uk/resources/386894", "AnsweringBody" : [{"_value" : "Department of Health"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/386894/answer", "answerText" : {"_value" : "

Information on high risk groups suffering neural tube defects at birth is not collected centrally.<\/p>

<\/p>

<\/p>

<\/p>

There are no current mechanisms in place for monitoring the take-up of advice given on the NHS Choices website about preventing spina bifida.<\/p>

<\/p>

<\/p>

<\/p>

The British Isles Network of Congenital Anomaly Registers (BINOCAR) collects information about the mother and child, including postcode of residence, mother\u2019s age, pregnancy length, pregnancy outcome, when and how the anomaly was identified and the details of each anomaly.<\/p>

<\/p>

<\/p>

<\/p>

Information on congenital abnormalities including spina bifida, hydrocephalus and anencephaly is collected by the British Isles Network of Congenital Anomaly Registers. Data is currently available for 2009\u20132012.<\/p>

<\/p>

<\/p>

<\/p>

The following table shows the number of live births for years 2009-2012<\/p>

<\/p>

<\/strong><\/p>

<\/p>

Number of cases, birth prevalence (per 10,000 total births) and 95% CIs according to congenital anomaly subgroup; six BINOCAR registers (coverage: 36% of births in England and Wales): 2009-2012 \u2013 Live Births<\/p><\/td><\/tr>

<\/p><\/td>

2009<\/p><\/td>

2010<\/p><\/td>

2011<\/p><\/td>

2012<\/p><\/td><\/tr>

Congenital anomaly<\/p>

<\/p><\/td>

<\/p><\/td>

<\/p><\/td>

<\/p><\/td>

<\/p><\/td><\/tr>

Spina bifida<\/p>

<\/p><\/td>

31<\/p><\/td>

53<\/p><\/td>

34<\/p><\/td>

44<\/p><\/td><\/tr>

Hydrocephalus<\/p>

<\/p><\/td>

48<\/p><\/td>

85<\/p><\/td>

72<\/p><\/td>

84<\/p><\/td><\/tr>

Anencephalus and similar<\/p>

<\/p><\/td>

4<\/p><\/td>

4<\/p><\/td>

1<\/p><\/td>

6<\/p><\/td><\/tr><\/tbody><\/table>

<\/p>

<\/strong><\/p>

<\/p>

In line with National Institute for Health and Care Excellence guidelines, health professionals use appropriate opportunities to advise all women who may become pregnant that they can most easily reduce the risk of having a baby with a neural tube defect by taking folic acid supplements. This information is also available on the NHS Choices website.<\/p>

<\/p>

<\/strong><\/p>

<\/p>

The Scientific Advisory Committee on Nutrition (SACN) was, however, commissioned to provide advice to government on the impact of folic acid fortification to improve the folate status of women and therefore reduce the number of pregnancies affected by neural tube defects. This built on previous advice from SACN\u2019s predecessor the Committee on Medical Aspects of Food and Nutrition Policy in 2000. The Government is currently considering the recommendations that SACN made alongside other information sources, including the latest folate status data and expects to make an announcement on this in due course.<\/p>

<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/127", "label" : {"_value" : "Biography information for Lord Prior of Brampton"} } , "answeringMemberPrinted" : {"_value" : "Lord Prior of Brampton"} , "dateOfAnswer" : {"_value" : "2015-07-14", "_datatype" : "dateTime"} , "groupedQuestionUIN" : [{"_value" : "HL1000"} , {"_value" : "HL1001"} , {"_value" : "HL1002"} , {"_value" : "HL1004"} , {"_value" : "HL1005"} ], "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2015-07-14T14:37:07.86Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "17"} , "answeringDeptShortName" : {"_value" : "Health"} , "answeringDeptSortName" : {"_value" : "Health"} , "date" : {"_value" : "2015-07-01", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Congenital Abnormalities"} , "houseId" : {"_value" : "2"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25277", "prefLabel" : {"_value" : "House of Lords"} } ], "questionText" : "To ask Her Majesty\u2019s Government whether the postcodes of mothers of babies born with congenital abnormalities are yet available on the British Isles Network of Congenital Anomaly Registers.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/302", "label" : {"_value" : "Biography information for Lord Rooker"} } , "tablingMemberPrinted" : [{"_value" : "Lord Rooker"} ], "uin" : "HL1003"} , {"_about" : "http://data.parliament.uk/resources/386895", "AnsweringBody" : [{"_value" : "Department of Health"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/386895/answer", "answerText" : {"_value" : "

Information on high risk groups suffering neural tube defects at birth is not collected centrally.<\/p>

<\/p>

<\/p>

<\/p>

There are no current mechanisms in place for monitoring the take-up of advice given on the NHS Choices website about preventing spina bifida.<\/p>

<\/p>

<\/p>

<\/p>

The British Isles Network of Congenital Anomaly Registers (BINOCAR) collects information about the mother and child, including postcode of residence, mother\u2019s age, pregnancy length, pregnancy outcome, when and how the anomaly was identified and the details of each anomaly.<\/p>

<\/p>

<\/p>

<\/p>

Information on congenital abnormalities including spina bifida, hydrocephalus and anencephaly is collected by the British Isles Network of Congenital Anomaly Registers. Data is currently available for 2009\u20132012.<\/p>

<\/p>

<\/p>

<\/p>

The following table shows the number of live births for years 2009-2012<\/p>

<\/p>

<\/strong><\/p>

<\/p>

Number of cases, birth prevalence (per 10,000 total births) and 95% CIs according to congenital anomaly subgroup; six BINOCAR registers (coverage: 36% of births in England and Wales): 2009-2012 \u2013 Live Births<\/p><\/td><\/tr>

<\/p><\/td>

2009<\/p><\/td>

2010<\/p><\/td>

2011<\/p><\/td>

2012<\/p><\/td><\/tr>

Congenital anomaly<\/p>

<\/p><\/td>

<\/p><\/td>

<\/p><\/td>

<\/p><\/td>

<\/p><\/td><\/tr>

Spina bifida<\/p>

<\/p><\/td>

31<\/p><\/td>

53<\/p><\/td>

34<\/p><\/td>

44<\/p><\/td><\/tr>

Hydrocephalus<\/p>

<\/p><\/td>

48<\/p><\/td>

85<\/p><\/td>

72<\/p><\/td>

84<\/p><\/td><\/tr>

Anencephalus and similar<\/p>

<\/p><\/td>

4<\/p><\/td>

4<\/p><\/td>

1<\/p><\/td>

6<\/p><\/td><\/tr><\/tbody><\/table>

<\/p>

<\/strong><\/p>

<\/p>

In line with National Institute for Health and Care Excellence guidelines, health professionals use appropriate opportunities to advise all women who may become pregnant that they can most easily reduce the risk of having a baby with a neural tube defect by taking folic acid supplements. This information is also available on the NHS Choices website.<\/p>

<\/p>

<\/strong><\/p>

<\/p>

The Scientific Advisory Committee on Nutrition (SACN) was, however, commissioned to provide advice to government on the impact of folic acid fortification to improve the folate status of women and therefore reduce the number of pregnancies affected by neural tube defects. This built on previous advice from SACN\u2019s predecessor the Committee on Medical Aspects of Food and Nutrition Policy in 2000. The Government is currently considering the recommendations that SACN made alongside other information sources, including the latest folate status data and expects to make an announcement on this in due course.<\/p>

<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/127", "label" : {"_value" : "Biography information for Lord Prior of Brampton"} } , "answeringMemberPrinted" : {"_value" : "Lord Prior of Brampton"} , "dateOfAnswer" : {"_value" : "2015-07-14", "_datatype" : "dateTime"} , "groupedQuestionUIN" : [{"_value" : "HL1000"} , {"_value" : "HL1001"} , {"_value" : "HL1002"} , {"_value" : "HL1003"} , {"_value" : "HL1005"} ], "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2015-07-14T14:37:07.987Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "17"} , "answeringDeptShortName" : {"_value" : "Health"} , "answeringDeptSortName" : {"_value" : "Health"} , "date" : {"_value" : "2015-07-01", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Neural Tube Defects"} , "houseId" : {"_value" : "2"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25277", "prefLabel" : {"_value" : "House of Lords"} } ], "questionText" : "To ask Her Majesty\u2019s Government what assessment they have made of the implications for health equality of their current policy regarding the prevention of neural tube defect-affected pregnancies.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/302", "label" : {"_value" : "Biography information for Lord Rooker"} } , "tablingMemberPrinted" : [{"_value" : "Lord Rooker"} ], "uin" : "HL1004"} ], "itemsPerPage" : 10, "next" : "http://eldaddp.azurewebsites.net/answeredquestions.text?date=2015-07-01&_page=1&answeringDeptId=17", "page" : 0, "startIndex" : 1, "totalResults" : 53, "type" : ["http://purl.org/linked-data/api/vocab#ListEndpoint", "http://purl.org/linked-data/api/vocab#Page"]} }